Artificial neural networks applied to the in vitro in vivo correlation of an extended-release formulation: Initial trials and experience

被引:41
作者
Dowell, JA
Hussain, A
Devane, J
Young, D
机构
[1] Univ Maryland, Dept Pharmaceut Sci, Pharmacokinet Biopharmaceut Lab, Invitro Invivo Relat Cooperat Working Grp, Baltimore, MD 21201 USA
[2] US FDA, Rockville, MD 20855 USA
[3] Elan Corp plc, Athlone, Ireland
关键词
D O I
10.1021/js970148p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Artificial neural networks applied to in vitro-in vivo correlations (ANN-IVIVC) have the potential to be a reliable predictive tool that overcomes some of the difficulties associated with classical regression methods, principally, that of providing an a priori specification of the regression equation structure. A number of unique ANN configurations are presented, that have been evaluated for their ability to determine an IVIVC from different formulations of the same product. Configuration variables included a combination of architectural structures, learning algorithms, and input-output association structures. The initial training set consisted of two formulations and included the dissolution from each of the six cells in the dissolution bath as inputs, with associated outputs consisting of 1512 pharmacokinetic time points from nine patients enrolled in a crossover study. A third formulation IVIVC data set was used for predictive validation. Using these data, a total of 29 ANN configurations were evaluated. The ANN structures included the traditional feed forward, recurrent, jump connections, and general regression neural networks, with input-output association types consisting of the direct mapping of the dissolution profiles to the pharmacokinetic observations, mapping the individual dissolution points to the individual observations, and using a "memorative" input-output association. The ANNs were evaluated on the basis of their predictive performance, which was excellent for some of these ANN models. This work provides a basic foundation for ANN-IVIVC modeling and is the basis for continued modeling with other desirable inputs, such as formulation variables and subject demographics.
引用
收藏
页码:154 / 160
页数:7
相关论文
共 21 条
[1]  
Anderson J. A., 1995, An Introduction to Neural Networks
[2]   DIFFERENTIAL ABSORPTION OF AMOXICILLIN FROM THE HUMAN SMALL AND LARGE-INTESTINE [J].
BARR, WH ;
ZOLA, EM ;
CANDLER, EL ;
HWANG, SM ;
TENDOLKAR, AV ;
SHAMBUREK, R ;
PARKER, B ;
HILTY, MD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :279-285
[3]   NEURAL-NETWORK PREDICTED PEAK AND TROUGH GENTAMICIN CONCENTRATIONS [J].
BRIER, ME ;
ZURADA, JM ;
ARONOFF, GR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :406-412
[4]   INVITRO INVIVO CORRELATION OF PROLONGED RELEASE DOSAGE FORMS CONTAINING DILTIAZEM HCL [J].
CARAMELLA, C ;
FERRARI, F ;
BONFERONI, MC ;
SANGALLI, ME ;
DIVALSERRA, MD ;
FELETTI, F ;
GALMOZZI, MR .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1993, 14 (02) :143-160
[5]   BACKPROPAGATION NEURAL NETS WITH ONE AND 2 HIDDEN LAYERS [J].
DEVILLIERS, J ;
BARNARD, E .
IEEE TRANSACTIONS ON NEURAL NETWORKS, 1993, 4 (01) :136-141
[6]   FINDING STRUCTURE IN TIME [J].
ELMAN, JL .
COGNITIVE SCIENCE, 1990, 14 (02) :179-211
[7]   INTRODUCTION TO BACKPROPAGATION NEURAL NETWORK COMPUTATION [J].
ERB, RJ .
PHARMACEUTICAL RESEARCH, 1993, 10 (02) :165-170
[8]   THE BACKPROPAGATION NEURAL-NETWORK - A BAYESIAN CLASSIFIER - INTRODUCTION AND APPLICABILITY TO PHARMACOKINETICS [J].
ERB, RJ .
CLINICAL PHARMACOKINETICS, 1995, 29 (02) :69-79
[9]  
Gallant S.I., 1993, Neural Network Learning and Expert Systems
[10]   QUANTITATIVE STRUCTURE-PHARMACOKINETIC RELATIONSHIPS (QSPR) OF BETA-BLOCKERS DERIVED USING NEURAL NETWORKS [J].
GOBBURU, JVS ;
SHELVER, WH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (07) :862-865